Manel Cascalló

Corporate Officer/Principal presso THERIVA BIOLOGICS, INC.

Commercial Services

Health Technology

Consumer Services

Profilo

Manel Cascalló is currently the Director General-European Region at Theriva Biologics, Inc. He was previously the Chairman & Chief Executive Officer at VCN Biosciences SL.
He obtained his undergraduate and doctorate degrees from the University of Barcelona.

Posizioni attive di Manel Cascalló

Società	Posizione	Inizio
THERIVA BIOLOGICS, INC.	Corporate Officer/Principal	23/03/2022

Tutte le posizioni attive di Manel Cascalló

Precedenti posizioni note di Manel Cascalló

Società	Posizione	Fine
VCN Biosciences SL VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million.	Amministratore Delegato	-

Vedi nel dettaglio l'esperienza di Manel Cascalló

Formazione di Manel Cascalló

University of Barcelona

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Manel Cascalló

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
THERIVA BIOLOGICS, INC.	Health Technology

Aziende private	1
VCN Biosciences SL VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million.	Commercial Services